产后出血的预防:从证据到大规模实施
产后出血是孕产妇死亡的主要原因,预防比单纯治疗可能产生更好结局。预防策略除宫缩剂外,还包括满足避孕需求、纠正贫血、优化基础疾病、控制剖宫产率及加强产前保健。一项Cochrane网状Meta分析纳入122项试验、121931名妇女,发现缩宫素联合米索前列醇或缩宫素联合麦角新碱预防效果最佳但副作用风险更高;单药中缩宫素和卡贝缩宫素最有效且副作用少。因此推荐缩宫素或卡贝缩宫素单药常规预防,无法获得时可用米索前列醇替代,高危孕妇可考虑联合方案,麦角新碱相关方案因高血压安全性担忧不再推荐。
要点
- Cochrane网状Meta分析(122项试验、121931名妇女)显示,缩宫素联合米索前列醇或缩宫素联合麦角新碱预防产后出血最有效,但副作用风险高于单药预防。
- 单药预防中缩宫素和卡贝缩宫素最有效且副作用少,推荐用于常规预防;无法获得缩宫素或卡贝缩宫素时,米索前列醇为替代选择。
- 产后出血高危孕妇可考虑缩宫素联合米索前列醇进行联合预防。
- 麦角新碱单用及缩宫素联合麦角新碱因高血压相关安全性担忧不再推荐。
- 剖宫产与产后出血风险显著增加相关,因此仅在具有医学指征时实施。
适用人群与场景
- 分娩时接受产后出血预防的孕产妇;高危孕妇可考虑联合预防方案。
- 需要关注的产品后出血可干预危险因素包括高BMI、多胎妊娠、妊娠期糖尿病、子痫前期、巨大儿及若干内科疾病。
处置流程与药物剂量
- 常规预防推荐单用缩宫素或卡贝缩宫素。
- 无法获得缩宫素或卡贝缩宫素时,米索前列醇为替代选择。
- 产后出血高危孕妇可考虑缩宫素联合米索前列醇进行联合预防。
- 不再推荐麦角新碱单用及缩宫素联合麦角新碱,原因为高血压相关安全性担忧。
- 预防产后出血还应包括:满足避孕需求、纠正贫血(处理月经过多、孕前或产前血红蛋白检测及口服或静脉铁治疗、改善饮食、罕见情况下输血)、优化易感内科疾病、控制剖宫产率(仅在医学指征时实施剖宫产)。
- 有效实施预防保健需要早期规律产前保健及在资源配备适当的卫生机构计划分娩。
研究设计与关键结果
- Cochrane网状Meta分析纳入122项试验、121931名妇女,发现分娩时给予缩宫素联合米索前列醇或缩宫素联合麦角新碱预防产后出血最有效,但联合方案副作用风险高于单药预防。
- 单药预防中缩宫素和卡贝缩宫素最有效且副作用极少。
- 剖宫产与产后出血风险大幅增加相关。
证据类型、等级与局限
- 证据类型:Cochrane网状Meta分析(122项试验,121931名妇女)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 常规产后出血预防应使用缩宫素或卡贝缩宫素单药;缩宫素或卡贝缩宫素不可及时可用米索前列醇替代。
- 产后出血高危孕妇可考虑缩宫素联合米索前列醇,但需注意联合方案副作用风险高于单药预防。
- 不应再使用麦角新碱单用或缩宫素联合麦角新碱方案,因高血压相关安全性担忧。
- 剖宫产仅在医学指征时实施,以降低产后出血风险。
- 实施预防策略需确保质量有保证的药品和器械供应、培训与支持以及持续的政治和财务承诺。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Postpartum haemorrhage (PPH) is a leading cause of maternal death. Preventing PPH can spare women from experiencing the trauma and risks of PPH, reduce the strain on overstretched health systems, and probably produce better outcomes than a strategy solely focused on PPH treatment. Prevention of PPH is often interpreted as provision of uterotonic drugs to contract the uterus at the time of childbirth. Although uterotonics are a central strategy for PPH prevention, several other approaches can prevent PPH or ameliorate its severity. These approaches include addressing the unmet need for contraception, remedying anaemia and other modifiable risk factors for PPH, optimising medical conditions that predispose to PPH, and tackling the rise in caesarean births in many countries. Effective delivery of preventive care requires early and regular antenatal care and planned birth at appropriately resourced health facilities. Social and behavioural change interventions for improving contraceptive provision and uptake, targeting adolescents, postpartum women, geographically remote communities, and families on low income, are a priority. Effective interventions to tackle anaemia include the management of heavy menstrual bleeding, pre-pregnancy or antenatal haemoglobin testing and oral or intravenous iron treatment, dietary improvements, and-on rare occasions-blood transfusion. Risk factors for PPH that need attention include high BMI, multiple pregnancy, gestational diabetes, pre-eclampsia, macrosomia, and several medical conditions. Caesarean births are associated with a substantial increase in PPH risk and should therefore only be done when medically indicated. A Cochrane network meta-analysis of 122 trials, with 121 931 women, found that the combinations of oxytocin plus misoprostol, or oxytocin plus ergometrine, were the most effective prophylaxis for PPH when given at the time of childbirth; however, these combinations had a higher risk of side-effects compared with single-drug prophylaxis. Oxytocin and carbetocin were the most effective single drugs for PPH prophylaxis, with minimal side-effects. Single uterotonic prophylaxis with either oxytocin or carbetocin is, therefore, recommended for routine prophylaxis. However, if oxytocin or carbetocin is not accessible, misoprostol is an alternative. Combination prophylaxis with oxytocin plus misoprostol can be considered for women at high risk of PPH. Ergometrine alone and oxytocin plus ergometrine combination are no longer recommended due to hypertension-related safety concerns. A robust implementation approach that engages various stakeholders to promote change, ensures the supply of quality-assured medicines and devices, provides training and support, and secures ongoing political and financial commitment is necessary to translate evidence into global impact.
参考来源
- Gallos ID, Sindhu KN, Yunas I, et al. Prevention of postpartum haemorrhage: from evidence to implementation at scale. Lancet. 2026. PMID: 42285117. doi:10.1016/S0140-6736(26)00903-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。